However, in line with previous studies from our and other groups, the SSTR antagonist JR11 clearly shows superiority to the SSTR agonist octreotate for targeting breast cancer, also in the endogenously SSTR2 expressing breast cancer cell line ZR75–1. This evidence concerns the gene SSTR2 and breast cancer.